Compare · ABOS vs RVMD
ABOS vs RVMD
Side-by-side comparison of Acumen Pharmaceuticals Inc. (ABOS) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABOS and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $42.84B, about 265.0x ABOS ($161.6M).
- Over the past year, ABOS is up 42.7% and RVMD is up 344.9% - RVMD leads by 302.2 points.
- RVMD has been more active in the news (19 items in the past 4 weeks vs 2 for ABOS).
- RVMD has more recent analyst coverage (25 ratings vs 12 for ABOS).
- Company
- Acumen Pharmaceuticals Inc.
- Revolution Medicines Inc.
- Price
- $2.24+0.22%
- $204.97+2.59%
- Market cap
- $161.6M
- $42.84B
- 1M return
- -25.58%
- -4.74%
- 1Y return
- +42.68%
- +344.86%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2020
- News (4w)
- 2
- 19
- Recent ratings
- 12
- 25
Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics for the treatment of Alzheimer's and other neurodegenerative diseases. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is based in Charlottesville, Virginia.
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest ABOS
- Acumen Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026
- Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
- SEC Form S-8 filed by Acumen Pharmaceuticals Inc.
- SEC Form 10-Q filed by Acumen Pharmaceuticals Inc.
- Acumen Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
- Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026
- Director Porter Derrell exercised 19,500 shares at a strike of $1.07 and sold $75,240 worth of shares (32,300 units at $2.33), decreasing direct ownership by 27% to 35,500 units (SEC Form 4)
- SEC Form 144 filed by Acumen Pharmaceuticals Inc.
Latest RVMD
- Director Anderson Elizabeth M exercised 5,070 shares at a strike of $1.12 and sold $1,958,016 worth of shares (10,143 units at $193.04) as part of a pre-agreed trading plan, decreasing direct ownership by 54% to 4,333 units (SEC Form 4)
- Goldman resumed coverage on Revolution Medicines with a new price target
- Officer Mancini Anthony sold $347,402 worth of shares (1,764 units at $196.94) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 40,352 units (SEC Form 4)
- Chief Development Officer Sandler Alan B. sold $67,941 worth of shares (341 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 0.64% to 52,868 units (SEC Form 4) to satisfy withholding tax
- Officer Mancini Anthony sold $353,449 worth of shares (1,774 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 42,116 units (SEC Form 4) (for tax liability)
- Officer Kelsey Stephen Michael sold $1,109,554 worth of shares (5,569 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 286,307 units (SEC Form 4) to satisfy withholding obligation
- Chief Operating Officer Horn Margaret A sold $989,613 worth of shares (4,967 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 149,680 units (SEC Form 4) (withholding tax)
- Officer Goldsmith Mark A sold $2,786,938 worth of shares (13,988 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 253,342 units (SEC Form 4) (for withholding tax)
- SVP & General Counsel Cislini Jeff sold $670,631 worth of shares (3,366 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 52,541 units (SEC Form 4) (tax liability)
- Chief Financial Officer Anders Jack sold $807,513 worth of shares (4,053 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 119,216 units (SEC Form 4) to satisfy withholding obligation